Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

Critical variables associated with nonbiodegradable osmotically controlled implants.

Wright JC.

AAPS J. 2010 Sep;12(3):437-42. doi: 10.1208/s12248-010-9199-8. Epub 2010 May 19. Review.

PMID:
20490735
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer.

Wright JC, Tao Leonard S, Stevenson CL, Beck JC, Chen G, Jao RM, Johnson PA, Leonard J, Skowronski RJ.

J Control Release. 2001 Jul 10;75(1-2):1-10.

PMID:
11451492
[PubMed - indexed for MEDLINE]
3.

Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs.

Cukierski MJ, Johnson PA, Beck JC.

Int J Toxicol. 2001 Nov-Dec;20(6):369-81.

PMID:
11797819
[PubMed - indexed for MEDLINE]
4.

Controlled drug release from implantable matrices based on hydrophobic polymers.

Di Colo G.

Biomaterials. 1992;13(12):850-6. Review.

PMID:
1457678
[PubMed - indexed for MEDLINE]
5.

Managing advanced prostate cancer with Viadur (leuprolide acetate implant).

Moul JW, Civitelli K.

Urol Nurs. 2001 Dec;21(6):385-8, 393-4; quiz 395-6. Review.

PMID:
11998504
[PubMed - indexed for MEDLINE]
6.

Leuprorelin implant (ALZA). DUROS, leuprolide acetate implant, leuprolide implant, Viadur.

[No authors listed]

Drugs R D. 1999 Dec;2(6):425-6. No abstract available.

PMID:
10763458
[PubMed - indexed for MEDLINE]
7.

DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months.

Rohloff CM, Alessi TR, Yang B, Dahms J, Carr JP, Lautenbach SD.

J Diabetes Sci Technol. 2008 May;2(3):461-7.

PMID:
19885211
[PubMed]
Free PMC Article
8.

Dosage form development, in vitro release kinetics, and in vitro-in vivo correlation for leuprolide released from an implantable multi-reservoir array.

Prescott JH, Krieger TJ, Lipka S, Staples MA.

Pharm Res. 2007 Jul;24(7):1252-61. Epub 2007 Mar 27.

PMID:
17387603
[PubMed - indexed for MEDLINE]
9.

Controlled diffusional release of dispersed solute drugs from biodegradable implants of various geometries.

Collins R, Paul Z, Reynolds DB, Short RF, Wasuwanich S.

Biomed Sci Instrum. 1997;33:137-42.

PMID:
9731349
[PubMed - indexed for MEDLINE]
10.
11.

Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.

Robinson MR, Baffi J, Yuan P, Sung C, Byrnes G, Cox TA, Csaky KG.

Exp Eye Res. 2002 Feb;74(2):309-17.

PMID:
11950241
[PubMed - indexed for MEDLINE]
12.

Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men.

Suvisaari J, Moo-Young A, Juhakoski A, Elomaa K, Saleh SI, Lähteenmäki P.

Contraception. 1999 Nov;60(5):299-303.

PMID:
10717782
[PubMed - indexed for MEDLINE]
13.

Therapeutic applications of implantable drug delivery systems.

Dash AK, Cudworth GC 2nd.

J Pharmacol Toxicol Methods. 1998 Jul;40(1):1-12. Review.

PMID:
9920528
[PubMed - indexed for MEDLINE]
14.
15.

Elementary osmotic pump for indomethacin.

Theeuwes F, Swanson D, Wong P, Bonsen P, Place V, Heimlich K, Kwan KC.

J Pharm Sci. 1983 Mar;72(3):253-8.

PMID:
6842377
[PubMed - indexed for MEDLINE]
16.

Development of a novel osmotically driven drug delivery system for weakly basic drugs.

Guthmann C, Lipp R, Wagner T, Kranz H.

Eur J Pharm Biopharm. 2008 Jun;69(2):667-74. doi: 10.1016/j.ejpb.2007.12.017. Epub 2007 Dec 28.

PMID:
18226884
[PubMed - indexed for MEDLINE]
17.

In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain.

Lesser GJ, Grossman SA, Leong KW, Lo H, Eller S.

Pain. 1996 May-Jun;65(2-3):265-72.

PMID:
8826516
[PubMed - indexed for MEDLINE]
18.

Implantable controlled release systems.

Langer R.

Pharmacol Ther. 1983;21(1):35-51. Review.

PMID:
6353438
[PubMed - indexed for MEDLINE]
19.

In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly(D,L-lactide-co-glycolide).

Wang G, Tucker IG, Roberts MS, Hirst LW.

Pharm Res. 1996 Jul;13(7):1059-64.

PMID:
8842045
[PubMed - indexed for MEDLINE]
20.

Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant.

Kato A, Kimura H, Okabe K, Okabe J, Kunou N, Ogura Y.

Invest Ophthalmol Vis Sci. 2004 Jan;45(1):238-44.

PMID:
14691179
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk